title: The Christchurch Breast Cancer Patient Register: the first year.
abstract: OBJECTIVE
  The aim of this article is to present the first year's findings of the Christchurch Breast Cancer Patient Register (CBCR) to establish the incidence and management of breast cancer in the Canterbury region.
  
  
  METHODS
  CBCR commenced recruitment of breast cancer patients in Canterbury from June 2009. Ethical approval was granted by regional ethics committees to collect data. Patient data is recorded onto the database once informed consent is obtained.
  
  
  RESULTS
  A total of 337 patients (including one male) consented. At diagnosis, 231 (68.5%) were aged 50 years or over. 48 (14.2%) patients had carcinoma in situ with no invasive component. 289 (85.8%) patients had invasive carcinoma with 47.4% undergoing mastectomy and 44.6% breast conserving surgery whereas 8% had no primary surgery. Nodes were positive in 102 (38.8%), and the predominant tumour type was Ductal NST (no special type) in 68.9% (199) of patients with invasive carcinoma. Additional data incorporating ethnicity, oncology, additional surgical management and pathological variables are also presented in detail.
  
  
  CONCLUSIONS
  Findings on 337 patients recruited and recorded on CBCR database in the first year are discussed. Due to the short follow up, outcome data is not analysed.
authors.affiliation: Christchurch Breast Cancer Patient Register, c/o Dept of Surgery, Christchurch Hospital, Private Bag 4710, Christchurch 8140, New Zealand. valerie.davey@cdhb.health.nz
authors.forename: Valerie
authors.initials: V
authors.lastname: Davey
authors.forename: Bridget
authors.initials: B
authors.lastname: Robinson
authors.forename: Birgit
authors.initials: B
authors.lastname: Dijkstra
authors.forename: Gavin
authors.initials: G
authors.lastname: Harris
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy*; D002278:Carcinoma in Situ / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D018270:Carcinoma, Ductal, Breast / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D018275:Carcinoma, Lobular / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D005006:Ethnicity / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D008408:Mastectomy / Q000706:statistics & numerical data; D015412:Mastectomy, Segmental / Q000706:statistics & numerical data; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D009520:New Zealand / Q000453:epidemiology; D018714:Radiotherapy, Adjuvant; D012042:Registries; D021701:Sentinel Lymph Node Biopsy / Q000706:statistics & numerical data; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D000068878:Trastuzumab